Table 1 Baseline characteristics of the study population
Characteristics | Bezafibrate (n = 58) | Placebo (n = 50) | p value |
|---|---|---|---|
Age, y | 61.1 ± 5.9 | 59.3 ± 6.2 | 0.12 |
Men (%) | 53 (91) | 46 (92) | 0.9 |
Past myocardial infarction (%) | 39 (67) | 36 (72) | 0.6 |
Angina (%) | 55 (95) | 47 (94) | 0.9 |
Hypertension (%) | 15 (26) | 17 (34) | 0.4 |
Current smokers (%) | 7 (12) | 6 (12) | 0.99 |
Past smokers (%) | 34 (59) | 30 (60) | 0.9 |
Body mass index (kg/m2) | 27.7 ± 3.8 | 27.1 ± 3.3 | 0.4 |
Systolic blood pressure, mmHg | 135 ± 18 | 133 ± 22 | 0.5 |
Diastolic blood pressure, mmHg | 81.1 ± 8.1 | 80.0 ± 10.2 | 0.4 |
Glucose, mg/dl | 103 ± 19 | 101 ± 19 | 0.7 |
Total cholesterol, mg/dl | 211 ± 17 | 215 ± 18 | 0.3 |
HDL-cholesterol, mg/dl | 35.4 ± 5.8 | 35.3 ± 5.1 | 0.9 |
LDL-cholesterol, mg/dl | 149 ± 15 | 152 ± 17 | 0.4 |
Fibrinogen, mg/dl | 348 ± 66 | 357 ± 70 | 0.5 |
Triglycerides, mg/dl | 127 (116–140) | 135 (124–147) | 0.4 |
CRP (mg/dl) | 4.23 (3.40–5.26) | 4.66 (3.49–6.23) | 0.6 |
Insulin, μU/ml | 4.14 (3.26–5.25) | 3.57 (2.70–4.73) | 0.4 |
HOMA-IR | 1.02 (0.79–1.31) | 0.88 (0.65–1.18) | 0.5 |
ProBNP, pg/ml | 154 (118–202) | 219 (168–284) | 0.07 |